Publication

Morenz A, Liao JM. 2025 Jan. Factoring neighborhood context into readmission risk: An outstanding question for health systems and policymakers. Journal of Hospital Medicine.

Feldman LER, Mohapatra S, Jones RT, Scholtes M, Tilton CB, Orman MV, Joshi M, Deiter CS, Broneske TP, Qu F, et al. 2024. Regulation of volume-regulated anion channels alters sensitivity to platinum chemotherapy. Science Advances. 10(50).

Morenz AM, Reddy A, Hsu A, Le A, Wong ES, Liao JM. 2024. Disparities in telemedicine use among Native Hawaiian and Pacific Islander individuals insured through Medicaid. Health Affairs Scholar. 2(5).

Lee D, Huntoon K, Wang Y, Kang M, Lu Y, Jeong SD, Link TM, Gallup TD, Qie Y, Li X, et al. 2024. Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nature Biomedical Engineering. 8(5):593–610.

Lou E, Xiu J, Baca Y, Saeed A, Prakash A, Gholami S, Subramanian S, Starr TK, Fontana E, Pandey R, et al. 2024. Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers. Molecular Therapy: Oncology. 32(1):200786.

Morrison C, Weterings E, Gravbrot N, Hammer M, Weinand M, Sanan A, Pandey R, Mahadevan D, Stea B. 2024. Gene Expression Patterns Associated with Survival in Glioblastoma. International Journal of Molecular Sciences. 25(7):3668.

Osipov A, Nikolic O, Gertych A, Parker S, Hendifar A, Singh P, Filippova D, Dagliyan G, Ferrone CR, Zheng L, et al. 2024. The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients. Nature Cancer. 5(2):299–314.

Zhang J, Rima XY, Wang X, Nguyen LTH, Huntoon K, Ma Y, Palacio PL, Nguyen KT, Albert K, Duong‐Thi M, et al. 2023. Engineering a tunable micropattern‐array assay to sort single extracellular vesicles and particles to detect RNA and protein in situ. Journal of Extracellular Vesicles. 12(11).

Zandbergen IM, Huntoon K, White TG, de Vries F, Moclair B, Van Furth WR, Pelsma ICM, Dehdashti A, Biermasz NR, Prevedello DM. 2023. FRI299 Efficacy And Safety Of Endoscopic Transsphenoidal Resection For Prolactinoma: A Retrospective Case-series. Journal of the Endocrine Society. 7(Supplement_1).

Van J, Alsayid M, Ma K, Vemulapalli K, Rex D, Melson J. 2023. Impact of Cold Snare vs Cold Forceps Resection of Diminutive Adenomas on Segmental Incomplete Resection Rate. Am J Gastroenterol. 118:1410–1418. doi:10.14309/ajg.0000000000002289.

Bresalier RS, Senore C, Young GP, Allison J, Benamouzig R, Benton S, Bossuyt PMM, Caro L, Carvalho B, Chiu H-M, et al. 2023 Jul. An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles. Gut. doi:10.1136/gutjnl-2023-329701.

Song H, Sontz RA, Vance MJ, Morris JM, Sheriff S, Zhu S, Duan S, Zeng J, Koeppe E, Pandey R, et al. 2023. High-fat diet plus HNF1A variant promotes polyps by activating β-catenin in early-onset colorectal cancer. JCI Insight. 8(13).

Abdel-Hafiz HA, Schafer JM, Chen X, Xiao T, Gauntner TD, Li Z, Theodorescu D. 2023. Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature. 619(7970):624–631.

de Jong FC, Laajala TD, Hoedemaeker RF, Jordan KR, van der Made AC, Boevé ER, van der Schoot DK, Nieuwkamer B, Janssen EA, Mahmoudi T, et al. 2023. Non–muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin. Science Translational Medicine. 15(697).

Batai K, Chen Y, Rheinheimer BA, Arora A, Pandey R, Heimark RL, Bracamonte ER, Ellis NA, Lee BR. 2023. Clear cell renal cell carcinoma molecular variations in <scp>non‐Hispanic</scp> White and Hispanic patients. Cancer Medicine. 12(11):12792–12801.

Maldonado A, Villavicencio EA, Vogel RM, Pace TW, Ruiz JM, Alkhouri N, Garcia DO. 2023. The association between perceived stress, acculturation, and non-alcoholic fatty liver disease in Mexican-origin adults in Southern Arizona. Preventive Medicine Reports. 32:102147.

Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I. 2023. The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert Rev Pharmacoecon Outcomes Res. 23:309–316. doi:10.1080/14737167.2023.2169135.

Abraham I. 2023. Trends, Changes, and Disruptions: The Fragile Economics of Cancer Treatments. Oncologist. 28:193–195. doi:10.1093/oncolo/oyac258.

Mantina N, Contreras J, Yellowhair M, Hatcher J. 2023. Abstract 4188: Multifaceted approach to engaging basic cancer scientists in community-based research. doi:10.1158/1538-7445.AM2023-4188.

Mantina N, Contreras J, Yellowhair M, Hatcher J. 2023. Building capacity for collaborative research between basic scientists and underrepresented communities in cancer research. doi:10.1007/s10552-023-01726-7.

Slomka B, Duan S, Knapp T, Lima N, Sontz R, Merchant J, Sawyer T. 2023. Design, fabrication, and preclinical testing of a miniaturized, multispectral, chip-on-tip, imaging probe for intraluminal fluorescence imaging of the gastrointestinal tract. Front. Biophotonics 3 (2023).

Ruiz J. M., Bacon S. L., Bennett G. G., Brondolo E., Czajkowski S. M., Davidson K. W., Epel E. S., Revenson T. A. 2023. on behalf of the Behavioral Medicine Research Council (2023). Behavioral Medicine Research Council (BMRC) Statement Papers: A new approach to consensus building in behavioral medicine science. Annals of Behavioral Medicine.

Alrawashdh N, McBride A, Erstad B, Sweasy J, Persky DO, Abraham I. 2022. Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia. Value Health. 25:1685–1695. doi:10.1016/j.jval.2022.04.001.

Chakrabarti J, Pandey R, Churko JM, Eschbacher J, Mallick S, Chen Y, Hermes B, Mallick P, Stansfield BN, Pond KW, et al. 2022. Development of Human Pituitary Neuroendocrine Tumor Organoids to Facilitate Effective Targeted Treatments of Cushing’s Disease. Cells. 11(21):3344.

You S, Kim M, Hoi XP, Lee YC, Wang L, Spetzler D, Abraham J, Magee D, Jain P, Galsky MD, et al. 2022. Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti–PD-L1 Immune Checkpoint Therapy. JNCI: Journal of the National Cancer Institute. 114(10):1380–1391.